Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Deferred Taxes (2016 - 2017)

CytomX Therapeutics' Deferred Taxes history spans 3 years, with the latest figure at -$520000.0 for Q4 2017.

  • For Q4 2017, Deferred Taxes changed N/A year-over-year to -$520000.0; the TTM value through Dec 2017 reached -$513000.0, down 8650.0%, while the annual FY2017 figure was -$513000.0, 8650.0% down from the prior year.
  • Deferred Taxes reached -$520000.0 in Q4 2017 per CTMX's latest filing, down from -$19000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $25000.0 in Q2 2017 to a low of -$520000.0 in Q4 2017.
  • Average Deferred Taxes over 3 years is -$72000.0, with a median of $3000.0 recorded in 2015.
  • The largest YoY upside for Deferred Taxes was 733.33% in 2017 against a maximum downside of 66.67% in 2017.
  • A 3-year view of Deferred Taxes shows it stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then crashed by 17433.33% to -$520000.0 in 2017.
  • Per Business Quant, the three most recent readings for CTMX's Deferred Taxes are -$520000.0 (Q4 2017), -$19000.0 (Q3 2017), and $25000.0 (Q2 2017).